05/12/2018 21:36:53

Constellation Brands to Report Third Quarter Fiscal 2019 Financial Results; Host Conference Call January 9, 2019

VICTOR, N.Y., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today it will report financial results for its fiscal third quarter ended November 30, 2018, on Wednesday, January 9, 2019, before the open of the U.S. markets. A conference call to discuss the financial results and outlook will be hosted by Chief Executive Officer Rob Sands, President and Chief Operating Officer Bill Newlands and Executive Vice President and Chief Financial Officer David Klein at 10:30 a.m. EST, January 9, 2019. 

The conference call can be accessed by dialing +1-877-673-1771 and entering conference identification number 5284499, beginning at 10:20 a.m. EST. A live, listen-only webcast of the conference call will be available on the company’s website, www.cbrands.com, under the Investors/Events & Presentations section. When the call begins, financial information discussed on the conference call, and a reconciliation of reported (GAAP) financial measures with comparable or non-GAAP financial measures, will also be available on the company’s website under Investors and by selecting Reporting. For anyone unable to participate in the conference call, a replay will be available on the company’s website.

About Constellation Brands

Constellation Brands (NYSE: STZ and STZ.B), a Fortune 500® company, is a leading international producer and marketer of beer, wine and spirits with operations in the U.S., Mexico, New Zealand, Italy and Canada. Constellation is the No. 3 beer company in the U.S. with high-end, iconic imported brands such as Corona Extra, Corona Light, Modelo Especial, Modelo Negra and Pacifico. The company’s beer portfolio also includes Ballast Point, one of the most awarded craft brewers in the U.S., and Funky Buddha Brewery. In addition, Constellation is the world leader in premium wine, selling great brands that people love, including Robert Mondavi, Clos du Bois, Kim Crawford, Meiomi, Mark West, Black Box, Ruffino and The Prisoner. The company’s premium spirits brands include SVEDKA Vodka, Casa Noble Tequila and High West Whiskey.

Based in Victor, N.Y., the company believes that industry leadership involves a commitment to brand building, our trade partners, the environment, our investors and to consumers around the world who choose our products when celebrating big moments or enjoying quiet ones. Founded in 1945, Constellation has grown to become a significant player in the beverage alcohol industry with more than 100 brands in its portfolio; about 40 wineries, breweries and distilleries; and approximately 10,000 talented employees. We express our company vision: to elevate life with every glass raised. To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

MEDIA CONTACTSINVESTOR RELATIONS CONTACTS 

Mike McGrew 773-251-4934  |  Amy Martin 585-678-7141

Patty Yahn-Urlaub 585-678-7483  |  Bob Czudak 585-678-7170

 

 

 

Tom Conaway 585-678-7503

 

PDF available: https://resource.globenewswire.com/Resource/Download/649e2735-8522-4ed8-ae3c-5693b97117b0

2_Color_Vert(R).jpg

Related content
30 May - 
Constellation Brands to Report First Quarter Fiscal 202..
15 May - 
Modelo Joins Forces with Leave No Veteran Behind throug..
07 May - 
Constellation Brands to Present at the Goldman Sachs Gl..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
2
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
3
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
4
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
5
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

Related stock quotes

Constellation Brands Inc 187.63 -0.9% Stock price decreasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 10:51:23
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB2 - 2019-06-16 11:51:23 - 2019-06-16 10:51:23 - 1000 - Website: OKAY